CANCER MARKET OPPORTUNITIES

There are significant unmet needs in first line advanced RCC.

LARGE MARKET OPPORTUNITY

  • Worldwide mRCC market est. > $2 billion
  • Est. 20,000-25,000 mRCC cases/year in U.S. alone

VIABLE TARGET

  • mRCC tumors are immuno-responsive
  • First line combination with SOC* oral therapy

TKI TOXICITIES

  • Substantial side-effects limit patient compliance
  • Overlapping toxicities result in sequential monotherapy SOC

LIMITED SOC EFFICACY IN NEWLY DIAGNOSED mRCC

  • Nephrectomy + Sunitinib/TKI is recommended standard of care
  • Median OS in TKI treated intermediate/poor risk patients ~ 15 months1

*SOC–Standard of Care (NCCN Guidelines)
1. Ko JJ et al. British Journal of Cancer (2014) 110, 1917-1922

Cancer Clinical Trials
Cancer Pipeline